Mesoblast Ltd
Company Profile
Business description
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Contact
55 Collins Street
Level 38
MelbourneVIC3000
AUST: +61 396396036
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
73
Stocks News & Analysis
stocks
Unconventional wisdom: Are dividends the answers?
stocks
Netflix: A business that’s nearly flawless
stocks
Trump’s US dollar assault is fuelling CBA’s rise
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,930.40 | 49.00 | -0.55% |
CAC 40 | 7,818.28 | 32.15 | -0.41% |
DAX 40 | 24,295.93 | 55.11 | 0.23% |
Dow JONES (US) | 44,693.91 | 316.38 | -0.70% |
FTSE 100 | 9,138.37 | 76.88 | 0.85% |
HKSE | 25,534.92 | 132.26 | -0.52% |
NASDAQ | 21,057.96 | 37.94 | 0.18% |
Nikkei 225 | 41,580.12 | 246.22 | -0.59% |
NZX 50 Index | 12,848.26 | 43.13 | 0.34% |
S&P 500 | 6,363.35 | 4.44 | 0.07% |
S&P/ASX 200 | 8,660.60 | 48.80 | -0.56% |
SSE Composite Index | 3,603.28 | 2.45 | -0.07% |